Tilray Brands, Inc. (TLRY)
USD 0.49
(-0.12%)
USD 0.49
(-0.12%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 | 387.31 Million USD | -34.37% |
| 2023 | 590.13 Million USD | -5.4% |
| 2022 | 623.8 Million USD | -33.54% |
| 2021 | 938.65 Million USD | 212.55% |
| 2020 | 300.32 Million CAD | -16.84% |
| 2019 | 361.11 Million CAD | 1397.9% |
| 2018 | 24.1 Million CAD | -2.84% |
| 2017 | 24.81 Million CAD | 0.0% |
| 2016 | - CAD | 0.0% |
| 2015 | - CAD | 0.0% |
| 2014 | - CAD | 0.0% |
| 2013 | - CAD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 529.38 Million USD | -5.92% |
| 2024 FY | 387.31 Million USD | -34.37% |
| 2024 Q4 | 387.31 Million USD | -19.58% |
| 2024 Q1 | 562.71 Million USD | -4.65% |
| 2024 Q3 | 481.61 Million USD | -9.02% |
| 2023 Q3 | 603.73 Million USD | -0.85% |
| 2023 Q1 | 657.81 Million USD | 5.45% |
| 2023 Q2 | 608.91 Million USD | -7.43% |
| 2023 Q4 | 590.13 Million USD | -2.25% |
| 2023 FY | 590.13 Million USD | -5.4% |
| 2022 Q2 | 799.77 Million USD | -8.47% |
| 2022 Q4 | 623.8 Million USD | -14.88% |
| 2022 FY | 623.8 Million USD | -33.54% |
| 2022 Q1 | 873.73 Million USD | -6.92% |
| 2022 Q3 | 732.87 Million USD | -8.37% |
| 2021 Q2 | 421.68 Million CAD | 29.9% |
| 2021 Q1 | 324.62 Million CAD | 8.09% |
| 2021 Q3 | 728.8 Million CAD | 72.83% |
| 2021 FY | 938.65 Million USD | 212.55% |
| 2021 Q4 | 938.65 Million USD | 28.79% |
| 2020 Q2 | 380.37 Million CAD | 7.25% |
| 2020 Q3 | 362.1 Million CAD | -4.8% |
| 2020 Q4 | 300.32 Million CAD | -17.06% |
| 2020 Q1 | 354.66 Million CAD | -1.79% |
| 2020 FY | 300.32 Million CAD | -16.84% |
| 2019 Q4 | 361.11 Million CAD | 513.53% |
| 2019 FY | 361.11 Million CAD | 1397.9% |
| 2019 Q2 | 41.54 Million CAD | -3.57% |
| 2019 Q3 | 58.85 Million CAD | 41.69% |
| 2019 Q1 | 43.07 Million CAD | 78.69% |
| 2018 FY | 24.1 Million CAD | -2.84% |
| 2018 Q3 | 30.26 Million CAD | 19.54% |
| 2018 Q4 | 24.1 Million CAD | -20.34% |
| 2018 Q2 | 25.31 Million CAD | -3.01% |
| 2018 Q1 | 26.1 Million CAD | 5.2% |
| 2017 Q3 | 6.66 Million CAD | 18.59% |
| 2017 Q1 | 5.9 Million CAD | 0.0% |
| 2017 Q2 | 5.61 Million CAD | -4.8% |
| 2017 Q4 | 24.81 Million CAD | 272.38% |
| 2017 FY | 24.81 Million CAD | 0.0% |
| 2016 Q1 | - CAD | 0.0% |
| 2016 Q2 | - CAD | 0.0% |
| 2016 Q4 | - CAD | 0.0% |
| 2016 FY | - CAD | 0.0% |
| 2016 Q3 | - CAD | 0.0% |
| 2015 Q3 | - CAD | 0.0% |
| 2015 Q2 | - CAD | 0.0% |
| 2015 Q1 | - CAD | 0.0% |
| 2015 FY | - CAD | 0.0% |
| 2015 Q4 | - CAD | 0.0% |
| 2014 Q4 | - CAD | 0.0% |
| 2014 Q3 | - CAD | 0.0% |
| 2014 Q2 | - CAD | 0.0% |
| 2014 Q1 | - CAD | 0.0% |
| 2014 FY | - CAD | 0.0% |
| 2013 Q1 | - CAD | 0.0% |
| 2013 Q4 | - CAD | 0.0% |
| 2013 FY | - CAD | 0.0% |
| 2013 Q3 | - CAD | 0.0% |
| 2013 Q2 | - CAD | 0.0% |
| 2012 Q2 | - CAD | 0.0% |
| 2012 Q3 | - CAD | 0.0% |
| 2012 Q4 | - CAD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 674.28 Million USD | 42.559% |
| Embecta Corp. | 1.63 Billion USD | 76.361% |
| ANI Pharmaceuticals, Inc. | 315.32 Million USD | -22.83% |
| Dynavax Technologies Corporation | 256.91 Million USD | -50.757% |
| Esperion Therapeutics, Inc. | 540.94 Million USD | 28.4% |
| Pacira BioSciences, Inc. | 586.04 Million USD | 33.91% |
| PainReform Ltd. | 86 Thousand USD | -450268.605% |
| Aquestive Therapeutics, Inc. | 98.82 Million USD | -291.934% |
| Sunshine Biopharma, Inc. | 657.7 Thousand USD | -58789.168% |
| SCYNEXIS, Inc. | 15.08 Million USD | -2468.415% |
| China SXT Pharmaceuticals, Inc. | 2.64 Million USD | -14529.786% |
| Cosmos Health Inc. | 12.42 Million USD | -3017.502% |
| Journey Medical Corporation | 17.73 Million USD | -2084.529% |
| Sunshine Biopharma, Inc. | 657.7 Thousand USD | -58789.168% |
| Safety Shot Inc | 1.54 Million USD | -24904.745% |
| Alpha Teknova, Inc. | 30.45 Million USD | -1171.643% |
| Intra-Cellular Therapies, Inc. | 16.93 Million USD | -2186.675% |
| Bright Green Corporation | 1.85 Million USD | -20815.896% |
| Procaps Group, S.A. | 285.93 Million USD | -35.456% |
| Theratechnologies Inc. | 58.96 Million USD | -556.826% |
| Harrow Health, Inc. | 190.5 Million USD | -103.314% |
| Sonoma Pharmaceuticals, Inc. | 608 Thousand USD | -63603.454% |
| Biofrontera Inc. | 5.39 Million USD | -7073.866% |
| DURECT Corporation | 20.74 Million USD | -1766.948% |
| Supernus Pharmaceuticals, Inc. | 41.52 Million USD | -832.687% |
| Cronos Group Inc. | 2.53 Million USD | -15149.073% |
| OptiNose, Inc. | 131.74 Million USD | -193.981% |
| Ironwood Pharmaceuticals, Inc. | 715.53 Million USD | 45.871% |
| Kala Pharmaceuticals, Inc. | 36.32 Million USD | -966.313% |
| RedHill Biopharma Ltd. | 1.17 Million USD | -32919.183% |
| Organogenesis Holdings Inc. | 119.35 Million USD | -224.519% |
| Guardion Health Sciences, Inc. | - USD | -Infinity% |
| Cumberland Pharmaceuticals Inc. | 18.42 Million USD | -2001.73% |
| Radius Health, Inc. | 365.31 Million USD | -6.023% |
| Universe Pharmaceuticals INC | 5.48 Million USD | -6964.662% |
| ProPhase Labs, Inc. | 21.38 Million USD | -1711.586% |
| Phibro Animal Health Corporation | 525.45 Million USD | 26.29% |
| Procaps Group S.A. | 285.93 Million USD | -35.456% |
| Alvotech | 1.07 Billion USD | 63.986% |
| TherapeuticsMD, Inc. | 8 Million USD | -4738.438% |
| Viatris Inc. | 18.12 Billion USD | 97.863% |
| Rockwell Medical, Inc. | 13.43 Million USD | -2782.037% |
| Aytu BioPharma, Inc. | 15.12 Million USD | -2460.097% |
| SIGA Technologies, Inc. | 1.46 Million USD | -26355.917% |
| Lifecore Biomedical, Inc. | 130.36 Million USD | -197.113% |
| Shineco, Inc. | 29.65 Million USD | -1206.013% |
| PetIQ, Inc. | 468.3 Million USD | 17.293% |
| Regencell Bioscience Holdings Limited | 59.8 Thousand USD | -647511.484% |
| Incannex Healthcare Limited | 373 Thousand USD | -103738.338% |
| Neurocrine Biosciences, Inc. | 428.4 Million USD | 9.59% |
| Alimera Sciences, Inc. | 67.39 Million USD | -474.663% |
| Silver Spike Investment Corp. | - USD | -Infinity% |
| Assertio Holdings, Inc. | 40.91 Million USD | -846.708% |
| Shuttle Pharmaceuticals Holdings, Inc. | 1.08 Million USD | -35509.004% |
| Petros Pharmaceuticals, Inc. | 8.27 Million USD | -4579.668% |
| Clever Leaves Holdings Inc. | 2.08 Million USD | -18458.553% |
| Cyclo Therapeutics, Inc. | 1.03 Million USD | -37390.212% |
| Avadel Pharmaceuticals plc | 35.38 Million USD | -994.611% |
| Hempacco Co., Inc. | 13.72 Million USD | -2722.084% |
| Talphera, Inc. | - USD | -Infinity% |
| Alvotech | 1.07 Billion USD | 63.986% |
| Eagle Pharmaceuticals, Inc. | 62.46 Million USD | -520.045% |
| Lantheus Holdings, Inc. | 616.94 Million USD | 37.22% |
| Currenc Group, Inc. | 31.94 Million USD | -1112.501% |
| Kamada Ltd. | 8.74 Million USD | -4326.993% |
| Indivior PLC | 281.6 Million USD | -37.541% |
| Evoke Pharma, Inc. | 5 Million USD | -7646.34% |
| Flora Growth Corp. | 3.67 Million USD | -10447.849% |
| Cyclo Therapeutics, Inc. | 1.03 Million USD | -37390.212% |
| Evolus, Inc. | 126.54 Million USD | -206.068% |
| HUTCHMED (China) Limited | 86.13 Million USD | -349.684% |
| Amphastar Pharmaceuticals, Inc. | 623.64 Million USD | 37.894% |
| Akanda Corp. | 3.99 Million USD | -9585.853% |